Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Oct 14, 2017 3:33am
410 Views
Post# 26813119

RE:My take on great news muted share price

RE:My take on great news muted share priceHey balain, I share your frustration. based on all the very positive PRs over the last year, I thought the sp should be closer to $4 than today's price. The issue has been the overhang of the weak B/S. Everybody knows this. One thing that has come thru in all my communications with the company is that fixing the B/S is the number one priority.

Q3 results are due by mid November. There is no doubt that this issue will come up and management will have to provide insight as to how it expects to finance operations until it is cashflow positive in 2019. So not long to wait.

Like you, I believe that it is possible if not likely that Thomvest will step up to the plate. I don't know whether this will be in the form of a loan or equity. I prefer a loan, in anticipation of PLI closing partnership/licencing deals. While PLI's hand in negotiations may appear to be slightly weakened because of its financial situation, this is likely to be more than offset by the fact that several very large pharmas are  likely tusseling with each other to get the rights to 4050 for IPF. We also can't exclude scope for regional deals on Pg either and PLI's hand has been strengthened with yesterday's news. The prospect of a  voucher is a wonderful wild card to have.

Let's see what happens over the next few weeks or months. I am hopeful that PLI will access all the rocket fuel it needs to get us to the moon.
Bullboard Posts